Hematological Diseases
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Starting from January 1, 2000, for patients diagnosed with hematopoietic stem cell deficiency syndromes, multiple myeloma, leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, coagulopathies, hematological genetic disorders, who have undergone hematopoietic stem cell transplantation or other hematological system-related conditions: 1. Clinical cohort: Collect demographic data, diagnostic and therapeutic information, prognostic indicators, and healthcare expenditure details from electronic medical records. 2. Multi-omics genomic landscape characterization: Obtain biological specimens, including bone marrow aspirates, biopsy tissues, peripheral blood, cerebrospinal fluid, etc. For invasive analyses only residual specimens from routine clinical testing, as per established guidelines, are to be collected without additional procedures; for non-invasive samples such as feces and buccal swabs, longitudinal sampling will be performed according to specific experimental protocols. Obtain informed consent and document participant agreement.
Exclusion criteria
Exclusion criteria: 1. Due to multiple factors, comprehensive longitudinal follow-up data for the subjects could not be secured. 2. Substance dependence, including alcohol and illicit drugs, impairs participants' adherence to study protocols. 3. Based on the investigators' assessment, certain conditions may pose safety risks or compromise participant compliance. 4. The subjects declined to provide informed consent for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate;Minimal residual disease;Quality of life; | — |
Countries
China
Contacts
Xijing Hospital, Air Force Military Medical University